Version history

{
  "session_id": "sess_SDA-2026-04-26-gap-20260425-224724",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "codex_task_runner",
  "action": "propose",
  "content": "Theorist assessment for gap gap-20260425-224724: How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegeneration through toll-like receptor TLR signaling and short-chain fatty acids SCFAs\n\nThe strongest causal model is that TLR4 priming interacts with SCFA depletion and then converges on microglial inflammasome tone. This is testable because the proposed drivers make temporally ordered predictions, not just cross-sectional associations. Three candidate hypotheses are:\n- TLR4 priming is the actionable driver in: How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegeneration th: The gap can be tested by treating TLR4 priming as an upstream driver rather than a passive correlate. If true, perturbing butyrate-restoring consortia should shift fecal butyrate before downstream neurodegeneration markers change.\n- plasma LPS-binding protein separates causal from compensatory states in: How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegenerat: A longitudinal biomarker panel centered on plasma LPS-binding protein can distinguish harmful mechanisms from protective adaptation. The decisive experiment is to measure plasma LPS-binding protein before and after TLR4 antagonism in stratified models.\n- microglial inflammasome tone defines the therapeutic window for: How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegener: The same signal may be beneficial early and damaging late. Testing microglial inflammasome tone with dietary fiber challenge should reveal a disease-stage interaction and define when intervention is protective versus counterproductive.\n\nKey predictions: fecal butyrate should move before clinical decline; plasma LPS-binding protein should stratify responders; and butyrate-restoring consortia should reduce the downstream inflammatory or proteostatic signature in model systems.",
  "hypotheses_referenced": "[\"h-gap-2f2e5b80-m1\", \"h-gap-2f2e5b80-m2\", \"h-gap-2f2e5b80-m3\"]",
  "evidence_cited": "[]",
  "tokens_used": "477",
  "persona_id": "persona-theorist"
}